Johnson & Johnson reported a strong Q3 2025 with 5.4% operational sales growth, driven by innovative medicine (5.3% growth excluding Stelara) and medtech (5.6%). Management raised full-year guidance, announced the spin-off of the orthopedics business, and provided a bullish preliminary 2026 outlook above consensus. Key pipeline highlights include the FDA approval of Inlexo for bladder cancer and strong growth of Tremfya and Carvykti. Q3 operational sales grew 5.4% to $24B, with innovative medicine up 5.3% (16% ex-Stelara) and medtech up 5.6%.
Buzzberg 분석J&J raises 2025 sales guidance, expects 2026 growth above consensusJohnson & Johnson reported a strong Q3 2025 with 5.4% operational sales growth, driven by innovative medicine (5.3% growth excluding Stelara) and medtech (5.6%). Management raised full-year guidance, announced the spin-off of the orthopedics business, and provided a bullish preliminary 2026 outlook above consensus. Key pipeline highlights include the FDA approval of Inlexo for bladder cancer and strong growth of Tremfya and Carvykti. Q3 operational sales grew 5.4% to $24B, with innovative medicine up 5.3% (16% ex-Stelara) and medtech up 5.6%.전체 분석 보기분석 접기
Johnson & Johnson reported a strong Q3 2025 with 5.4% operational sales growth, driven by innovative medicine (5.3% growth excluding Stelara) and medtech (5.6%). Management raised full-year guidance, announced the spin-off of the orthopedics business, and provided a bullish preliminary 2026 outlook above consensus. Key pipeline highlights include the FDA approval of Inlexo for bladder cancer and strong growth of Tremfya and Carvykti. Q3 operational sales grew 5.4% to $24B, with innovative medicine up 5.3% (16% ex-Stelara) and medtech up 5.6%.
Management raised 2025 operational sales guidance by ~$300M, reaffirmed adjusted EPS of $10.80-$10.90, and guided for ~300bps margin improvement.
Announced the planned separation of the orthopedics business (DePuy Synthes) within 18-24 months to sharpen focus on high-growth areas.
Pipeline momentum: Inlexo FDA approval for bladder cancer, Tremfya IBD launch growing 40%, Carvykti on track for $5B peak, and Rylave+Lastclues Phase III data.
Management emphasized strong momentum, accelerating growth, and raised guidance, while expressing optimism about future pipeline and portfolio separation.
수요 및 자본지출
수요
수주 및 전환
Spravato growth 61%, treated 180k patients, expanding. Management emphasized strong momentum, accelerating growth, and raised guidance, while expressing optimism about future pipeline and portfolio separation.
자본지출
투자 및 생산능력
Management reiterated a commitment to invest $55 billion in U.S.-based innovation and manufacturing over the next four years, including new facilities in North Carolina and other expansions, highlighting increased U.S. manufacturing footprint due to tax policy.
톤 · Confident
Management emphasized strong momentum, accelerating growth, and raised guidance, while expressing optimism about future pipeline and portfolio separation.
공급망 알파
A1
JNJ is dedicating a 160,000+ sq ft manufacturing facility at Fujifilm's Holly Springs site, signaling a strategic push to onshore advanced biopharma production and reliance on Fujifilm's contract manufacturing capabilities.
“a $2 billion commitment ... a more than 160,000 square foot dedicated manufacturing facility at Fujifilm's new biopharmaceutical manufacturing site in Holly Springs”
JNJ is expanding U.S. biopharmaceutical manufacturing at a Fujifilm site, deepening a partnership that should provide steady contract manufacturing revenue for Fujifilm.
“we announced a $2 billion commitment to further increase our presence in North Carolina, with a more than 160,000 square foot dedicated manufacturing facility at Fujifilm's new biopharmaceutical manufacturing site”
… Act. We feel strongly that U.S. tax policy has enabled Johnson & Johnson to increase our manufacturing footprint in the U.S. We have more manufacturing facilities in the United States than in any other country, and we remain committed to investing $55 billion in U.S.-based innovation and manufacturing over the next four years. In March, we broke ground at our Wilson, North Carolina facility, and in August, we announced a $2 billion commitment to further increase our presence in North Carolina, with a more than 160,000 square foot dedicated manufacturing facility at Fujifilm's new biopharmaceutical manufacturing site in Holly Springs. Our overall U.S. investment plans also include three additional new advanced manufacturing facilities, as well as the expansion of several existing sites. Turning to earnings per share, you may recall we started the year guiding to adjusted EPS of $10.60. Today, we stand much higher, even after including dilution of $0.25 from the intercellular acquisition. Today, we are reaffirming our elevated July earnings per share outlook, which also absorbs a higher annual effective tax rate and fourth quarter investments that will further position the …
JNJ is dedicating a 160,000+ sq ft manufacturing facility at Fujifilm's Holly Springs site, signaling a strategic push to onshore advanced biopharma production and reliance on Fujifilm's contract manufacturing capabilities.